Alere's revenue soars; MRI Global to develop anthrax blood Dx

> Alere ($ALR) said it generated nearly $754 million in revenue during the 2013 third quarter, an increase due, in part, to healthy gains in diagnostics sales. But the Massachusetts company lost $24.8 million. Release

> LabCorp ($LH) said it expects to refinance some debt and plans to issue senior notes in two tranches that will mature in 5 and 10 years, respectively. Item

> Researchers believe they've come up with a blood test that could predict a baby's genetic risk of diabetes from birth. Story (sub. req.)

> Enzo Biochem ($ENZ) said it will market Sequenom's ($SQNM) early noninvasive prenatal laboratory test service in the northeast U.S. Item

> Seattle's Indi, or Integrated Diagnostics, unveiled a protein expression blood test this week designed to help determine if lung nodules found during early screening are benign and don't need to be taken out. Story

> MRI Global has a $1.6 million contract from the U.S. Department of Health and Human Services to develop a quick blood test for anthrax detection if a chemical attack hits. Item

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.